Optimising workflows

We provide solutions for customers working across cell line development:

Vaccine Technology and Production with Mammalian Cells

Isolate, screen and characterise attributes for clones producing novel recombinant sub-unit protein and monoclonal antibody vaccines

Read More >

Novel Biotherapeutics and Biosimilars

Generate stable cell lines to create producing novel recombinant proteins e.g. monoclonal antibodies or therapeutic proteins for rare diseases

Read More >

Gene Therapy

Develop new, stable, producer cell lines manufacturing viruses to subsequently infect target cells of patients

Read More >

Gene Editing & Cell Engineering

Optimise your drug discovery process using targeted gene editing to create stable cell lines as cellular reagents, for use in target validation, functional genomics and disease modelling

Read More >

VIEW OUR WEBINAR

"How a Top-5 Pharma Doubled the Speed of Cell Line Development"

Latest News

Solentim appoints new sales manager for USA East

Solentim is pleased to announce the appointment of Jake Isaacs to the role of Sales Manager, USA East Coast. Jake is based in the Greater Boston area and holds a

Rapid on-boarding of the VIPS platform helped provide a competitive edge for Biotech start-up and a successful IND outcome

As the pressures on cell line development (CLD) laboratories are ever-increasing to expand into the expression of new modalities, you need a cell line development workflow that seamlessly works from

Solentim and ATUM to bundle Leap-In Transposase® with the VIPS™ single cell cloning instrument for cell line development

Bournemouth, UK and Newark, CA, USA, 20th April 2020 / Solentim, a global leader in cell line development (CLD) instrumentation, and bioengineering company ATUM, today announced that Solentim will bundle access

Podcast | Novel Methodologies for Rapid Vaccine Production

Novel methodologies for rapid vaccine production In this Podcast, Mark Stockdale and Duncan Borthwick discuss COVID-19 and developments in vaccine production methodologies with reference to a paper from GSK ,

GSK pioneer a single-step cloning strategy to generate novel recombinant sub unit vaccine candidates.

GSK Vaccines’ team shows the benefits of a new single-step cloning strategy to reduce effort and timelines to generate CHO cell lines expressing novel vaccine candidates. Currently we are living

Podcast | Viral Production for Gene Therapy

Moving towards clinical grade production In the latest edition of this Podcast series, Duncan Borthwick speaks to Mark Stockdale about the developing regulatory landscape around viral production for clinical gene